You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCanagliflozin
Accession NumberDB08907
TypeSmall Molecule
GroupsApproved
DescriptionCanagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered. FDA approved on March 29, 2013.
Structure
Thumb
Synonyms
Canagliflozin anhydrous
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Invokanatablet100 mgoralJanssen Inc2014-06-03Not applicableCanada
Invokanatablet300 mgoralJanssen Inc2014-05-28Not applicableCanada
Invokanatablet, film coated100 mg/1oralJanssen Pharmaceuticals, Inc.2013-03-29Not applicableUs
Invokanatablet, film coated300 mg/1oralJanssen Pharmaceuticals, Inc.2013-03-29Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
InvokametJanssen Pharmaceuticals, Inc.
Salts
Name/CASStructureProperties
Canagliflozin hydrate
928672-86-0
Thumb
  • InChI Key: VHOFTEAWFCUTOS-TUGBYPPCSA-N
  • Monoisotopic Mass: 906.291911168
  • Average Mass: 907.05
DBSALT001783
Categories
UNII6S49DGR869
CAS number842133-18-0
WeightAverage: 444.516
Monoisotopic: 444.140672805
Chemical FormulaC24H25FO5S
InChI KeyInChIKey=XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
InChI
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][C@]1(O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassGlycosyl compounds
Direct ParentPhenolic glycosides
Alternative Parents
Substituents
  • Phenolic glycoside
  • C-glycosyl compound
  • 2,5-disubstituted thiophene
  • Toluene
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Oxane
  • Monosaccharide
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Thiophene
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organofluoride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationCanagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended.
PharmacodynamicsCanagliflozin binds to SGLT2 more potently (250-times) than SGLT1 in vitro. The 50% inhibitory concentrations (IC50) are 2.2-4.4 nmol/L and 684 - 910 nmol/L for SGLT2 and SGLT1 respectively. Dose dependent decreases in renal threshold for glucose and increases in urinary glucose excretion were observed when single and multiple oral doses were administered to type 2 diabetes patients. Decreases in plasma glucose in a dose-dependent fashion were also noted as early as the first day of administration. When given to healthy and type 2 diabetic patients before a meal, a delay in intestinal glucose absorption and a reduction in postprandial glucose was observed. Canagliflozin does not prolong the QTc interval.
Mechanism of actionSodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion.
Related Articles
AbsorptionThe pharmacokinetics of canagliflozin is similar in healthy subjects and patients with type 2 diabetes. Plasma Cmax and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. Accumulation in plasma has been observed following multiple doses of 100 - 300 mg. Food does not affect the absorption of canagliflozin. Tmax = 1- 2 hours; Cmax = 1059 - 3148 ng/mL; Time to steady state, once daily dose, 100 - 300 mg = 4-5 days; Absolute oral bioavailability = 65%.
Volume of distribution

Steady state, single IV infusion, healthy subject = 119 L. This high value suggests that cangliflozin is extensively distributed to tissue.

Protein binding>99% protein bound, mainly to albumin. It also binds to alpha-acid glycoprotein. Protein binding is independent of canagliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.
Metabolism

Canagliflozin is hepatically metabolized via O-glucuronidation into two inactive O-glucuronide metabolites. The enzymes that facilitate this process are UGT1A9 and UGT2B4. To a lesser extent (7%), canagliflozin also undergoes oxidative metabolism via CYP3A4. Canagliflozin weakly inhibited CYP2B6, CYP2C8, CYP2C9, and CYP3A4 based on in vitro studies with human hepatic microsomes.

Route of eliminationEnterohepatic circulation of canagliflozin was negligible. When a single oral dose is administered to a healthy subject, canagliflozin is eliminated via the following: Feces (41.5%, 7.0%, 3.2% as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively). Urine (33%; 30.5% as O-glucuronide metabolite, <1% as unchanged drug).
Half lifeThe apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.
Clearance

Mean systemic clearance, healthy subjects, IV administration = 192 mL/min.
Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min.

ToxicityMost common adverse reactions associated with canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9541
Blood Brain Barrier+0.7708
Caco-2 permeable-0.6554
P-glycoprotein substrateSubstrate0.6058
P-glycoprotein inhibitor INon-inhibitor0.8414
P-glycoprotein inhibitor IINon-inhibitor0.9447
Renal organic cation transporterNon-inhibitor0.8544
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8293
CYP450 3A4 substrateNon-substrate0.5929
CYP450 1A2 substrateNon-inhibitor0.6579
CYP450 2C9 inhibitorNon-inhibitor0.6178
CYP450 2D6 inhibitorNon-inhibitor0.8683
CYP450 2C19 inhibitorNon-inhibitor0.5958
CYP450 3A4 inhibitorNon-inhibitor0.7086
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7691
Ames testNon AMES toxic0.584
CarcinogenicityNon-carcinogens0.9103
BiodegradationNot ready biodegradable0.9936
Rat acute toxicity2.5975 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9912
hERG inhibition (predictor II)Non-inhibitor0.7246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral
Tablet, film coatedoral
Tabletoral100 mg
Tabletoral300 mg
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral300 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7943582 No2009-02-262029-02-26Us
US7943788 No2007-07-142027-07-14Us
US8222219 No2004-07-302024-07-30Us
US8513202 No2007-12-032027-12-03Us
US8785403 No2004-07-302024-07-30Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP3.09ALOGPS
logP3.52ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.15 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity116.14 m3·mol-1ChemAxon
Polarizability46.5 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]
External Links
ATC CodesA10BD16A10BX11
AHFS Codes
  • 68:20.18
PDB EntriesNot Available
FDA labelDownload (683 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Canagliflozin.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Canagliflozin.
AcetaminophenThe serum concentration of Canagliflozin can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Canagliflozin.
AcetohexamideCanagliflozin may increase the hypoglycemic activities of Acetohexamide.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Canagliflozin.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Canagliflozin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Canagliflozin.
AlbendazoleThe serum concentration of Canagliflozin can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.
AldosteroneThe serum concentration of Canagliflozin can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Canagliflozin.
AlectinibThe serum concentration of Canagliflozin can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Canagliflozin can be increased when it is combined with Alfentanil.
AliskirenCanagliflozin may increase the hyperkalemic activities of Aliskiren.
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Canagliflozin.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Canagliflozin.
AmantadineThe serum concentration of Canagliflozin can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Canagliflozin.
AmilorideCanagliflozin may increase the hyperkalemic activities of Amiloride.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Canagliflozin.
Aminohippuric acidThe serum concentration of Canagliflozin can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Canagliflozin.
AmiodaroneThe serum concentration of Canagliflozin can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Canagliflozin can be increased when it is combined with Amitriptyline.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Canagliflozin.
AmobarbitalAmobarbital may increase the hypotensive activities of Canagliflozin.
AmoxapineAmoxapine may increase the hypoglycemic activities of Canagliflozin.
AmprenavirThe serum concentration of Canagliflozin can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Canagliflozin can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Canagliflozin.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Canagliflozin.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Canagliflozin.
AprepitantThe serum concentration of Canagliflozin can be increased when it is combined with Aprepitant.
ArdeparinArdeparin may increase the hyperkalemic activities of Canagliflozin.
AripiprazoleAripiprazole may increase the hypotensive activities of Canagliflozin.
Arsenic trioxideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Canagliflozin.
ArticaineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.
AstemizoleThe serum concentration of Canagliflozin can be increased when it is combined with Astemizole.
AtazanavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Atazanavir.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Canagliflozin.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Canagliflozin.
AtomoxetineThe metabolism of Canagliflozin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Canagliflozin can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Canagliflozin.
AzelastineThe serum concentration of Canagliflozin can be increased when it is combined with Azelastine.
Azilsartan medoxomilCanagliflozin may increase the hyperkalemic activities of Azilsartan medoxomil.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Canagliflozin.
AzithromycinThe serum concentration of Canagliflozin can be increased when it is combined with Azithromycin.
BarbitalBarbital may increase the hypotensive activities of Canagliflozin.
BemiparinBemiparin may increase the hyperkalemic activities of Canagliflozin.
BenazeprilCanagliflozin may increase the hyperkalemic activities of Benazepril.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Canagliflozin.
BendroflumethiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Bendroflumethiazide.
BenmoxinBenmoxin may increase the hypoglycemic activities of Canagliflozin.
BenzocaineThe serum concentration of Canagliflozin can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Canagliflozin can be increased when it is combined with Bepridil.
BetamethasoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Betamethasone.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Canagliflozin.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Canagliflozin.
BexaroteneThe serum concentration of Canagliflozin can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Canagliflozin can be increased when it is combined with Biperiden.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Canagliflozin.
BoceprevirThe metabolism of Canagliflozin can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Canagliflozin.
BortezomibThe metabolism of Canagliflozin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Canagliflozin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Canagliflozin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin.
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Canagliflozin.
BrexpiprazoleThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Canagliflozin.
BromocriptineThe serum concentration of Canagliflozin can be increased when it is combined with Bromocriptine.
BumetanideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bumetanide.
BumetanideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Bumetanide.
BuprenorphineThe serum concentration of Canagliflozin can be increased when it is combined with Buprenorphine.
BuserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin.
BuspironeThe serum concentration of Canagliflozin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Canagliflozin can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Canagliflozin can be increased when it is combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Canagliflozin.
CandesartanCanagliflozin may increase the hyperkalemic activities of Candesartan.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Canagliflozin.
CandoxatrilCanagliflozin may increase the hyperkalemic activities of Candoxatril.
CaptoprilCanagliflozin may increase the hyperkalemic activities of Captopril.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Canagliflozin.
CarbamazepineThe serum concentration of Canagliflozin can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Canagliflozin.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Canagliflozin.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Canagliflozin.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Canagliflozin.
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Canagliflozin.
CaspofunginThe serum concentration of Canagliflozin can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Canagliflozin can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Canagliflozin.
CertoparinCertoparin may increase the hyperkalemic activities of Canagliflozin.
ChloroquineThe serum concentration of Canagliflozin can be increased when it is combined with Chloroquine.
ChlorothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.
ChlorothiazideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Chlorothiazide.
ChlorpromazineThe serum concentration of Canagliflozin can be increased when it is combined with Chlorpromazine.
ChlorpropamideCanagliflozin may increase the hypoglycemic activities of Chlorpropamide.
ChlorpropamideThe serum concentration of Canagliflozin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Canagliflozin can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Chlorthalidone.
CholesterolThe serum concentration of Canagliflozin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Canagliflozin can be decreased when it is combined with Cholic Acid.
CilazaprilCanagliflozin may increase the hyperkalemic activities of Cilazapril.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Canagliflozin.
CimetidineThe serum concentration of Canagliflozin can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Canagliflozin.
CiprofloxacinThe serum concentration of Canagliflozin can be increased when it is combined with Ciprofloxacin.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Canagliflozin.
CitalopramCitalopram may increase the hypoglycemic activities of Canagliflozin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Canagliflozin.
ClarithromycinThe serum concentration of Canagliflozin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Canagliflozin can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Canagliflozin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Canagliflozin.
ClofazimineThe serum concentration of Canagliflozin can be increased when it is combined with Clofazimine.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Canagliflozin.
ClomipramineClomipramine may increase the hypoglycemic activities of Canagliflozin.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Canagliflozin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Canagliflozin.
ClotrimazoleThe metabolism of Canagliflozin can be decreased when combined with Clotrimazole.
ClozapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Canagliflozin.
CobicistatThe serum concentration of Canagliflozin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Canagliflozin.
ColchicineThe serum concentration of Canagliflozin can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Canagliflozin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Canagliflozin can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Canagliflozin.
CorticotropinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cortisone acetate.
CrizotinibThe metabolism of Canagliflozin can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Canagliflozin.
CyclophosphamideThe serum concentration of Canagliflozin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Canagliflozin can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Canagliflozin.
Cyproterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Canagliflozin.
DabrafenibThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Canagliflozin.
DaclatasvirThe serum concentration of Canagliflozin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Canagliflozin can be increased when it is combined with Dactinomycin.
DalteparinDalteparin may increase the hyperkalemic activities of Canagliflozin.
DanazolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Danazol.
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Canagliflozin.
DapoxetineDapoxetine may increase the hypoglycemic activities of Canagliflozin.
DarunavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Darunavir.
DasatinibThe serum concentration of Canagliflozin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Canagliflozin can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Canagliflozin.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Canagliflozin.
DeferasiroxThe serum concentration of Canagliflozin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Canagliflozin can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Canagliflozin can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Canagliflozin can be increased when it is combined with Desloratadine.
DesogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Canagliflozin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Canagliflozin.
DextromethorphanThe serum concentration of Canagliflozin can be increased when it is combined with Dextromethorphan.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Canagliflozin.
DiazoxideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.
DiclofenacThe serum concentration of Canagliflozin can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.
DienogestThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Canagliflozin.
DiflunisalDiflunisal may increase the hypoglycemic activities of Canagliflozin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Canagliflozin.
DigoxinThe serum concentration of Canagliflozin can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Canagliflozin.
DihydroergotamineThe metabolism of Canagliflozin can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Canagliflozin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Canagliflozin.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Canagliflozin.
DinutuximabThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Canagliflozin.
DisopyramideCanagliflozin may increase the hypoglycemic activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Canagliflozin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Canagliflozin.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.
DoxepinThe serum concentration of Canagliflozin can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Canagliflozin can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Canagliflozin.
DoxycyclineThe metabolism of Canagliflozin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Canagliflozin can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Canagliflozin can be decreased when combined with Dronedarone.
DrospirenoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.
DuloxetineCanagliflozin may increase the orthostatic hypotensive activities of Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Canagliflozin.
EfavirenzThe serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Canagliflozin can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Canagliflozin.
EmpagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Empagliflozin.
EnalaprilCanagliflozin may increase the hyperkalemic activities of Enalapril.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Canagliflozin.
EnalaprilatCanagliflozin may increase the hyperkalemic activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Canagliflozin.
EnzalutamideThe serum concentration of Canagliflozin can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Canagliflozin.
EpinephrineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.
EplerenoneCanagliflozin may increase the hyperkalemic activities of Eplerenone.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Canagliflozin.
EprosartanCanagliflozin may increase the hyperkalemic activities of Eprosartan.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Canagliflozin.
ErgonovineThe serum concentration of Canagliflozin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Canagliflozin can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Canagliflozin.
ErythromycinThe metabolism of Canagliflozin can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Canagliflozin.
EscitalopramEscitalopram may increase the hypoglycemic activities of Canagliflozin.
Eslicarbazepine acetateThe serum concentration of Canagliflozin can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Canagliflozin.
EstradiolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estradiol.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Canagliflozin.
EstramustineThe serum concentration of Canagliflozin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Canagliflozin can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Canagliflozin.
EstroneThe serum concentration of Canagliflozin can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Canagliflozin.
Estrone sulfateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estrone sulfate.
Etacrynic acidThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etacrynic acid.
Etacrynic acidThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Etacrynic acid.
Ethinyl EstradiolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinyl Estradiol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Canagliflozin.
Ethynodiol diacetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol diacetate.
EtonogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Canagliflozin.
EtoposideThe serum concentration of Canagliflozin can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Canagliflozin can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Canagliflozin.
EverolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Everolimus.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Canagliflozin.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Canagliflozin.
FenfluramineFenfluramine may increase the hypoglycemic activities of Canagliflozin.
FentanylThe serum concentration of Canagliflozin can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Canagliflozin.
FexofenadineThe serum concentration of Canagliflozin can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Canagliflozin can be increased when it is combined with Fidaxomicin.
FluconazoleThe metabolism of Canagliflozin can be decreased when combined with Fluconazole.
FludrocortisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fludrocortisone.
FluoxetineFluoxetine may increase the hypoglycemic activities of Canagliflozin.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Canagliflozin.
FlupentixolThe serum concentration of Canagliflozin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Canagliflozin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Canagliflozin can be increased when it is combined with Flurazepam.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Canagliflozin.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Canagliflozin.
ForasartanCanagliflozin may increase the hyperkalemic activities of Forasartan.
FosamprenavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.
FosaprepitantThe serum concentration of Canagliflozin can be increased when it is combined with Fosaprepitant.
FosinoprilCanagliflozin may increase the hyperkalemic activities of Fosinopril.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Canagliflozin.
FosphenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Canagliflozin.
FurosemideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Furosemide.
FurosemideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Furosemide.
Fusidic AcidThe serum concentration of Canagliflozin can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Canagliflozin can be increased when it is combined with Gefitinib.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Canagliflozin.
GenisteinThe serum concentration of Canagliflozin can be increased when it is combined with Genistein.
GlibornurideCanagliflozin may increase the hypoglycemic activities of Glibornuride.
GliclazideCanagliflozin may increase the hypoglycemic activities of Gliclazide.
GlimepirideCanagliflozin may increase the hypoglycemic activities of Glimepiride.
GlipizideCanagliflozin may increase the hypoglycemic activities of Glipizide.
GliquidoneCanagliflozin may increase the hypoglycemic activities of Gliquidone.
GlisoxepideCanagliflozin may increase the hypoglycemic activities of Glisoxepide.
GlyburideCanagliflozin may increase the hypoglycemic activities of Glyburide.
GlyburideThe serum concentration of Canagliflozin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Canagliflozin can be increased when it is combined with Glycerol.
GoserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.
Gramicidin DThe serum concentration of Canagliflozin can be increased when it is combined with Gramicidin D.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Canagliflozin.
GrepafloxacinThe serum concentration of Canagliflozin can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Canagliflozin.
HaloperidolThe serum concentration of Canagliflozin can be increased when it is combined with Haloperidol.
HeparinHeparin may increase the hyperkalemic activities of Canagliflozin.
HexobarbitalHexobarbital may increase the hypotensive activities of Canagliflozin.
HistrelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Canagliflozin.
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Canagliflozin.
HydrochlorothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocortisone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Canagliflozin.
HydroflumethiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroflumethiazide.
Hydroxyprogesterone caproateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Canagliflozin.
IdelalisibThe serum concentration of Canagliflozin can be increased when it is combined with Idelalisib.
IloperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.
ImatinibThe metabolism of Canagliflozin can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Canagliflozin.
ImipramineThe serum concentration of Canagliflozin can be increased when it is combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Canagliflozin.
IndalpineIndalpine may increase the hypoglycemic activities of Canagliflozin.
IndapamideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.
IndapamideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Indapamide.
IndinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Canagliflozin.
IndomethacinThe serum concentration of Canagliflozin can be increased when it is combined with Indomethacin.
Insulin AspartCanagliflozin may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirCanagliflozin may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineCanagliflozin may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineCanagliflozin may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanCanagliflozin may increase the hypoglycemic activities of Insulin Human.
Insulin LisproCanagliflozin may increase the hypoglycemic activities of Insulin Lispro.
Insulin PorkCanagliflozin may increase the hypoglycemic activities of Insulin Pork.
IproclozideIproclozide may increase the hypoglycemic activities of Canagliflozin.
IproniazidIproniazid may increase the hypoglycemic activities of Canagliflozin.
IrbesartanCanagliflozin may increase the hyperkalemic activities of Irbesartan.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Canagliflozin.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Canagliflozin.
IsavuconazoniumThe metabolism of Canagliflozin can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Canagliflozin.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Canagliflozin.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Canagliflozin.
IsoxsuprineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Canagliflozin.
ItraconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Canagliflozin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Canagliflozin can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Canagliflozin can be increased when it is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Canagliflozin.
KetoconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Ketoconazole.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Canagliflozin.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Canagliflozin.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Canagliflozin.
LanreotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lanreotide.
LanreotideCanagliflozin may increase the hypoglycemic activities of Lanreotide.
LansoprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Canagliflozin can be increased when it is combined with Lapatinib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Canagliflozin.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Canagliflozin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Canagliflozin.
LeuprolideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Canagliflozin.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Canagliflozin.
LevodopaCanagliflozin may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Canagliflozin can be increased when it is combined with Levofloxacin.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Canagliflozin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Canagliflozin.
LevonorgestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.
LevothyroxineThe serum concentration of Canagliflozin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Canagliflozin can be increased when it is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Canagliflozin.
LiothyronineThe serum concentration of Canagliflozin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Canagliflozin can be decreased when it is combined with Liotrix.
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Canagliflozin.
LisinoprilCanagliflozin may increase the hyperkalemic activities of Lisinopril.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Canagliflozin.
LomitapideThe serum concentration of Canagliflozin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Canagliflozin can be increased when it is combined with Loperamide.
LopinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lopinavir.
LoratadineThe serum concentration of Canagliflozin can be increased when it is combined with Loratadine.
LosartanCanagliflozin may increase the hyperkalemic activities of Losartan.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Canagliflozin.
LovastatinThe metabolism of Canagliflozin can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Canagliflozin.
LuliconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Canagliflozin can be decreased when it is combined with Lumacaftor.
LurasidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Canagliflozin.
MaprotilineThe serum concentration of Canagliflozin can be increased when it is combined with Maprotiline.
MebanazineMebanazine may increase the hypoglycemic activities of Canagliflozin.
MebendazoleThe serum concentration of Canagliflozin can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Canagliflozin.
MecaserminCanagliflozin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.
MefloquineThe serum concentration of Canagliflozin can be increased when it is combined with Mefloquine.
Megestrol acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Megestrol acetate.
MeprobamateThe serum concentration of Canagliflozin can be increased when it is combined with Meprobamate.
MesalazineMesalazine may increase the hypoglycemic activities of Canagliflozin.
MestranolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Mestranol.
MethadoneThe serum concentration of Canagliflozin can be increased when it is combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Canagliflozin.
MethohexitalMethohexital may increase the hypotensive activities of Canagliflozin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Canagliflozin.
MethotrimeprazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Methyclothiazide.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Canagliflozin.
Methylene blueMethylene blue may increase the hypoglycemic activities of Canagliflozin.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Canagliflozin.
MethylprednisoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methylprednisolone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Canagliflozin.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Canagliflozin.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Canagliflozin.
MetolazoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.
MetolazoneThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Metolazone.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Canagliflozin.
MibefradilThe serum concentration of Canagliflozin can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Canagliflozin can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Canagliflozin.
MifepristoneCanagliflozin may increase the hypoglycemic activities of Mifepristone.
MifepristoneThe metabolism of Canagliflozin can be decreased when combined with Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Canagliflozin.
MinaprineMinaprine may increase the hypoglycemic activities of Canagliflozin.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Canagliflozin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Canagliflozin.
MitomycinThe serum concentration of Canagliflozin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Canagliflozin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Canagliflozin can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Canagliflozin.
MoclobemideMoclobemide may increase the hypoglycemic activities of Canagliflozin.
ModafinilThe serum concentration of Canagliflozin can be decreased when it is combined with Modafinil.
MoexiprilCanagliflozin may increase the hyperkalemic activities of Moexipril.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Canagliflozin.
MorphineThe serum concentration of Canagliflozin can be increased when it is combined with Morphine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Canagliflozin.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Canagliflozin.
NadroparinNadroparin may increase the hyperkalemic activities of Canagliflozin.
NafcillinThe serum concentration of Canagliflozin can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Canagliflozin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Canagliflozin.
NaltrexoneThe serum concentration of Canagliflozin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Canagliflozin can be increased when it is combined with Naringenin.
NateglinideCanagliflozin may increase the hypoglycemic activities of Nateglinide.
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Canagliflozin.
NefazodoneThe serum concentration of Canagliflozin can be decreased when it is combined with Nefazodone.
NelfinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Canagliflozin.
NeostigmineThe serum concentration of Canagliflozin can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Canagliflozin.
NetupitantThe serum concentration of Canagliflozin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Canagliflozin can be decreased when combined with Nevirapine.
NiacinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.
NialamideNialamide may increase the hypoglycemic activities of Canagliflozin.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Canagliflozin.
NicorandilNicorandil may increase the hypotensive activities of Canagliflozin.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Canagliflozin.
NilotinibThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nilotinib.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Canagliflozin.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Canagliflozin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Canagliflozin.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Canagliflozin.
NitrazepamThe serum concentration of Canagliflozin can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Canagliflozin can be increased when it is combined with Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Canagliflozin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Canagliflozin.
NorethisteroneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethisterone.
NorgestimateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norgestimate.
OctamoxinOctamoxin may increase the hypoglycemic activities of Canagliflozin.
OctreotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Octreotide.
OctreotideCanagliflozin may increase the hypoglycemic activities of Octreotide.
OlanzapineOlanzapine may increase the hypoglycemic activities of Canagliflozin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Canagliflozin.
OlaparibThe metabolism of Canagliflozin can be decreased when combined with Olaparib.
OlmesartanCanagliflozin may increase the hyperkalemic activities of Olmesartan.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Canagliflozin.
OmapatrilatCanagliflozin may increase the hyperkalemic activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Canagliflozin.
OmeprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Canagliflozin can be increased when it is combined with Osimertinib.
OxandroloneOxandrolone may increase the hypoglycemic activities of Canagliflozin.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Canagliflozin.
P-NitrophenolThe serum concentration of Canagliflozin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Canagliflozin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Canagliflozin can be increased when it is combined with Palbociclib.
PaliperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.
Palmitic AcidThe serum concentration of Canagliflozin can be increased when it is combined with Palmitic Acid.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Canagliflozin.
PantoprazoleThe serum concentration of Canagliflozin can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.
PargylinePargyline may increase the hypoglycemic activities of Canagliflozin.
ParnaparinParnaparin may increase the hyperkalemic activities of Canagliflozin.
ParoxetineParoxetine may increase the hypoglycemic activities of Canagliflozin.
PasireotideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pasireotide.
PasireotideCanagliflozin may increase the hypoglycemic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.
PegvisomantPegvisomant may increase the hypoglycemic activities of Canagliflozin.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Canagliflozin.
PentamidineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentamidine.
PentamidineCanagliflozin may increase the hypoglycemic activities of Pentamidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Canagliflozin.
PerindoprilCanagliflozin may increase the hyperkalemic activities of Perindopril.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Canagliflozin.
PhenelzinePhenelzine may increase the hypoglycemic activities of Canagliflozin.
PheniprazinePheniprazine may increase the hypoglycemic activities of Canagliflozin.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Canagliflozin.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Canagliflozin.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Canagliflozin.
PhenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Canagliflozin.
PimozideThe serum concentration of Canagliflozin can be increased when it is combined with Pimozide.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Canagliflozin.
PiperazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Piperazine.
PipotiazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.
PiretanideCanagliflozin may increase the hypotensive activities of Piretanide.
PirlindolePirlindole may increase the hypoglycemic activities of Canagliflozin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Canagliflozin.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Canagliflozin.
Platelet Activating FactorThe serum concentration of Canagliflozin can be decreased when it is combined with Platelet Activating Factor.
PolythiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Canagliflozin.
PonatinibThe serum concentration of Canagliflozin can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Canagliflozin can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Canagliflozin can be increased when it is combined with Pravastatin.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Canagliflozin.
PrednisoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisolone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Canagliflozin.
PrednisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Canagliflozin.
PrimidonePrimidone may increase the hypotensive activities of Canagliflozin.
ProbenecidThe serum concentration of Canagliflozin can be increased when it is combined with Probenecid.
ProgesteroneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Canagliflozin.
PromethazineThe serum concentration of Canagliflozin can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Canagliflozin can be increased when it is combined with Propafenone.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Canagliflozin.
ProtriptylineThe serum concentration of Canagliflozin can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Canagliflozin.
QuercetinThe serum concentration of Canagliflozin can be increased when it is combined with Quercetin.
QuetiapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Quetiapine.
QuinacrineThe serum concentration of Canagliflozin can be increased when it is combined with Quinacrine.
QuinaprilCanagliflozin may increase the hyperkalemic activities of Quinapril.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Canagliflozin.
QuinethazoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quinethazone.
QuinidineThe serum concentration of Canagliflozin can be increased when it is combined with Quinidine.
QuinineCanagliflozin may increase the hypoglycemic activities of Quinine.
QuinineThe serum concentration of Canagliflozin can be increased when it is combined with Quinine.
RamiprilCanagliflozin may increase the hyperkalemic activities of Ramipril.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Canagliflozin.
RanitidineThe serum concentration of Canagliflozin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Canagliflozin.
RasagilineRasagiline may increase the hypoglycemic activities of Canagliflozin.
ReboxetineThe serum concentration of Canagliflozin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Canagliflozin can be increased when it is combined with Regorafenib.
RepaglinideCanagliflozin may increase the hypoglycemic activities of Repaglinide.
RescinnamineCanagliflozin may increase the hyperkalemic activities of Rescinnamine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Canagliflozin.
ReviparinReviparin may increase the hyperkalemic activities of Canagliflozin.
RifabutinThe metabolism of Canagliflozin can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Canagliflozin.
RifapentineThe metabolism of Canagliflozin can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Canagliflozin.
RilpivirineThe serum concentration of Canagliflozin can be increased when it is combined with Rilpivirine.
RiociguatThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Riociguat.
RisperidoneCanagliflozin may increase the hypotensive activities of Risperidone.
RisperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Canagliflozin.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Canagliflozin.
RolapitantThe serum concentration of Canagliflozin can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Canagliflozin.
SafrazineSafrazine may increase the hypoglycemic activities of Canagliflozin.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Canagliflozin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Canagliflozin.
SaprisartanCanagliflozin may increase the hyperkalemic activities of Saprisartan.
SaquinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Canagliflozin.
SaralasinCanagliflozin may increase the hyperkalemic activities of Saralasin.
ScopolamineThe serum concentration of Canagliflozin can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Canagliflozin.
SelegilineSelegiline may increase the hypoglycemic activities of Canagliflozin.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Canagliflozin.
SertralineSertraline may increase the hypoglycemic activities of Canagliflozin.
SildenafilThe metabolism of Canagliflozin can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Canagliflozin.
SiltuximabThe serum concentration of Canagliflozin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Canagliflozin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Canagliflozin can be increased when it is combined with Simvastatin.
SirolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Canagliflozin.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Canagliflozin.
SorafenibThe serum concentration of Canagliflozin can be increased when it is combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Canagliflozin.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Canagliflozin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Canagliflozin.
SpiraprilCanagliflozin may increase the hyperkalemic activities of Spirapril.
SpironolactoneCanagliflozin may increase the hyperkalemic activities of Spironolactone.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Canagliflozin.
St. John's WortThe serum concentration of Canagliflozin can be decreased when it is combined with St. John&#39;s Wort.
StanozololStanozolol may increase the hypoglycemic activities of Canagliflozin.
StaurosporineThe serum concentration of Canagliflozin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Canagliflozin can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Canagliflozin can be decreased when it is combined with Streptozocin.
SulfadiazineCanagliflozin may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleCanagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Canagliflozin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleCanagliflozin may increase the hypoglycemic activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Canagliflozin can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Canagliflozin can be increased when it is combined with Sumatriptan.
SunitinibCanagliflozin may increase the hypoglycemic activities of Sunitinib.
SunitinibThe serum concentration of Canagliflozin can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Canagliflozin can be increased when it is combined with Tacrine.
TacrolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Canagliflozin.
TamoxifenThe serum concentration of Canagliflozin can be decreased when it is combined with Tamoxifen.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Canagliflozin.
TasosartanCanagliflozin may increase the hyperkalemic activities of Tasosartan.
Taurocholic AcidThe serum concentration of Canagliflozin can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Canagliflozin.
TelaprevirThe metabolism of Canagliflozin can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Canagliflozin.
TelithromycinThe metabolism of Canagliflozin can be decreased when combined with Telithromycin.
TelmisartanCanagliflozin may increase the hyperkalemic activities of Telmisartan.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Canagliflozin.
TemocaprilCanagliflozin may increase the hyperkalemic activities of Temocapril.
TemsirolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Temsirolimus.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Canagliflozin.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.
TerfenadineThe serum concentration of Canagliflozin can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Canagliflozin can be decreased when it is combined with Tesmilifene.
TestosteroneTestosterone may increase the hypoglycemic activities of Canagliflozin.
ThiamylalThiamylal may increase the hypotensive activities of Canagliflozin.
ThiopentalThiopental may increase the hypotensive activities of Canagliflozin.
TicagrelorThe serum concentration of Canagliflozin can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Canagliflozin can be decreased when combined with Ticlopidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Canagliflozin.
TinzaparinTinzaparin may increase the hyperkalemic activities of Canagliflozin.
TipranavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Canagliflozin.
TocilizumabThe serum concentration of Canagliflozin can be decreased when it is combined with Tocilizumab.
TolazamideCanagliflozin may increase the hypoglycemic activities of Tolazamide.
TolbutamideCanagliflozin may increase the hypoglycemic activities of Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Canagliflozin.
TolvaptanThe serum concentration of Canagliflozin can be increased when it is combined with Tolvaptan.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Canagliflozin.
TorasemideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Torasemide.
TorasemideThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Torasemide.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Canagliflozin.
TrandolaprilCanagliflozin may increase the hyperkalemic activities of Trandolapril.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Canagliflozin.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Canagliflozin.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Canagliflozin.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Canagliflozin.
TrazodoneTrazodone may increase the hypoglycemic activities of Canagliflozin.
TriamcinoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triamcinolone.
TriamtereneCanagliflozin may increase the hyperkalemic activities of Triamterene.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Canagliflozin.
TrichlormethiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.
TrifluoperazineThe serum concentration of Canagliflozin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Canagliflozin can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Canagliflozin can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Canagliflozin can be increased when it is combined with Trimipramine.
TriptorelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.
TroleandomycinThe serum concentration of Canagliflozin can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Canagliflozin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Canagliflozin.
ValsartanCanagliflozin may increase the hyperkalemic activities of Valsartan.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Canagliflozin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Canagliflozin.
VenlafaxineThe metabolism of Canagliflozin can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Canagliflozin.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Canagliflozin.
VilazodoneVilazodone may increase the hypoglycemic activities of Canagliflozin.
VinblastineThe serum concentration of Canagliflozin can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Canagliflozin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Canagliflozin.
VincristineThe serum concentration of Canagliflozin can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Canagliflozin can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Canagliflozin.
VoriconazoleThe metabolism of Canagliflozin can be decreased when combined with Voriconazole.
VorinostatThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.
VortioxetineVortioxetine may increase the hypoglycemic activities of Canagliflozin.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Canagliflozin.
ZimelidineZimelidine may increase the hypoglycemic activities of Canagliflozin.
ZiprasidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Low-affinity glucose:sodium symporter activity
Specific Function:
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A2
Uniprot ID:
P31639
Molecular Weight:
72895.995 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Glucose:sodium symporter activity
Specific Function:
Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A1
Uniprot ID:
P13866
Molecular Weight:
73497.275 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
Comments
comments powered by Disqus
Drug created on June 17, 2013 00:21 / Updated on September 28, 2016 02:27